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Abstract 
Cancer is the leading cause of non-accidental death in children. Pediatric ependymomas (PE) 
are the third most common brain tumor in children. Despite advances leading to better survival 
outcomes in some cancers, these tumors remain incurable in up to 45% of patients, with 
recurrent local relapse being the major cause of mortality[18, 19]. Surgical resection is currently 
the most effective treatment, but over 50% of children whose tumors have been totally resected 
will still experience tumor recurrence despite aggressive adjuvant therapy [22]. Key molecular 
events in the pathogenesis of PE have yet to be defined, and understanding these events are 
proving to be increasingly necessary to developing clinically-relevant applications. In particular, 
errors in epigenetic regulatory machinery appear to play a substantial role in the pathogenesis of 
numerous cancers. As such, this research used gene expression profiling data on a large cohort 
(n=102) of PE samples to search for potential driving mechanisms underlying recurrence and 
poor prognosis in this cancer. Through this, we developed a model for the role of the histone 
modifying enzyme SUV4-20H2 in carcinogenesis. SUV4-20H2 confers modifications that lead 
to chromatin compaction and resultant silencing of genes in component/surrounding DNA. We 
hypothesized that this enzyme acts to directly regulate proto-oncogenes and that its loss in this 
cancer leads to their increased  expression. We find evidence to support this model for 
SUV4-20H2 regulation of TERT, the catalytic subunit of telomerase. This holds significant 
translational value as TERT is strongly associated with recurrence and has been shown to 
increase tumorigenicity of tumor initiating cells, and a better understanding of it's regulation 
could lead to development of new therapies. Additionally, these findings implicate a potential 
broader role of SUV4-20H2 in driving carcinogenesis and warrant further investigation. 
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Introduction 
Cancer epigenomics is an emerging concentration of clinical cancer research. In 
conjunction with the field of oncogenomics, research aims to better define genomic, 
transcriptomic and proteomic differences within individual tumor subtypes and between 
subtypes and to relate these determined molecular phenotypic patterns to differences in 
prognosis and treatment response. Studies of cancer genomics led to vast leaps in 
understanding of the nature and underlying mechanisms of cancer. These new understandings 
began to point toward errors in regulatory control of essential cell processes as fundamental to 
cancer development and progression. However, of the key cancer-causing genes identified to 
date, germline mutations in these genes only account for a small fraction of their observed 
aberrant expression. This leaves open the question of how these hallmark mutations arise. 
Further, findings began and continue to emerge indicating the presence of mutations in various 
components of epigenetic machinery in numerous cancers. Findings such as these point to a 
substantial role for epigenetics in driving cancer.  
Research in this area has also been driven by its increasing clinical relevance. One major 
problem in clinical cancer research to date has been connecting diagnosis to prognosis and 
treatment response. Significant heterogeneity in both prognosis and treatment response have 
been found in cancers diagnosed by histology and location, but these remain the two primary 
diagnostic criteria. As such, research directed at cancer types defined by these criteria is limited 
in scope and applicability. More recent efforts aimed at identifying classes of transcriptomic 
patterning have proven far better at predicting prognosis and treatment response and have the 
potential to reveal more regarding the mechanisms by which malignancies arise. A shift towards 
gene expression-profile based diagnostics should allow for huge advances in treatment and in 
research as we begin to be able to categorize cancers by the underlying mechanisms of their 
malignancy. 
This thesis examines the altered gene expression patterns in pediatric ependymoma 
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(PE), and subsequently investigates the role of a particular epigenetic factor in its prognosis. 
This introduction will (1) present an overview of our current understanding of epigenetic states 
and cancer, (2) identify and justify experimental aims and practices in studying epigenetics in 
cancer, (3) provide background on the specific malignancy being studied and explain why it is an 
excellent candidate for investigation, and (4) describe in further detail the epigenetic changes 
that will be the ultimate focus of this thesis. 
Epigenetics in Cancer  
Epigenetic changes are now considered to be of equal importance as genetic changes in 
carcinogenesis [1]. Broadly, epigenetic changes that lead to cancer involve improper silencing of 
tumor suppressor genes or activation of oncogenes. ‘Tumor suppressor’ describes genes that 
protect a cell from one step towards becoming cancerous. These genes tend to act as repressors 
at various stages of the cell cycle or induce processes leading to apoptosis. So-called ‘oncogenes’ 
are genes that, when activated, can cause cells destined for apoptosis or quiescence to instead 
survive and proliferate. ‘Proto-oncogenes’ are genes that are essential to cellular function at 
normal levels but which become ‘oncogenes’ when expressed at aberrantly high levels [2]. 
Mechanisms by which this can occur can be grouped into changes of epigenetic state at the DNA 
level and changes at the chromatin level, both of which will now be discussed further. Figure 1 
provides a general picture of what will be discussed. 
Epigenetic state at the DNA level is determined by the patterning of methylation of CpG 
dinucleotides. CpG is shorthand for “cytosine-phosphate-guanine” and describes the occurrence 
of a cytosine and guanine in direct sequence. This arrangement allows for a methyl group to be 
added to the cytosine nucleotide. CpG methylation can impact gene expression by way of two 
mechanisms: (1) methylated residues directly interfere with transcription factor binding, and (2) 
MBD (methyl-binding domain) proteins recognize and bind methyl-CpG’s and recruit other 
proteins (generally those involved in chromatin compaction). In normal cells, CpG islands 
preceding active gene promoters are usually unmethylated, those preceding promoters of 
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constitutively silenced genes are usually heavily methylated, and there is sporadic methylation 
of individual CpG dinucleotides throughout the genome. This is “inverted” in cells that become 
tumorigenic [3]. Commonly observed is hypermethylation of CpG islands preceding tumor 
suppressor genes, hypomethylation of promoter proximal CpG islands of oncogenes, and 
hypomethylation of repeat sequences and transposable elements (creates genomic instability). 
Overall, cancerous cells generally contain significantly fewer (20-50%) methylated cytosines [4]. 
This genome-wide hypomethylation can lead to such drastic effects as failure of chromosomes to 
separate properly in mitosis by promoting mitotic recombination and chromosome 
rearrangement [5]. Methylated cytosines also can be more easily hydrolyzed and spontaneously 
converted to thymine. Alterations in CpG island methylation lead to altered gene expression 
profiles and overall genome destabilization. 
 Changes at the chromatin level are more complex due to the number of different 
interacting components that yield its variable structure. The functional subunits of chromatin 
are called nucleosomes, and consist of DNA strands wound around proteins called histones. 
There are four types of histone proteins (H2A, H2B, H3, H4), and each nucleosome contains two 
units of a complex of those variants. All of these histone types are subject to many different 
types of modifications. Proteins involved in these processes are broadly termed chromatin 
remodeling proteins, and the enzymes that specifically catalyze the addition or removal of 
functional groups are termed histone modifying enzymes. Modifications induce various 
conformational changes which in aggregate can have impacts at the chromosome level and 
individually lead to changes in accessibility of the genes in their vicinity. They thereby regulate 
genomic stability both structurally and transcriptionally [6, 7]. 
 Aberrant changes in levels and localization of modifications can occur un-catalyzed, by 
“spreading” to nearby regions when conditions are favorable (e.g. loss of “insulator” protein), or 
catalyzed as a result of defects in the “epigenetic machinery” (i.e. histone modifying enzymes). 
Increases in modifications that silence tumor suppressor genes and that facilitate expression of 
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oncogenes, and corresponding decreases in modifications that silence oncogenes and that 
promote expression of tumor suppressor genes can lead to carcinogenesis [3].  
 Recent research has revealed that the genes involved in epigenetic regulation and 
chromatin remodeling are mutated at a very high frequency in a wide variety of cancers. 
Mutations in these types of genes, as discussed, contribute to and may in many cases drive the 
high degree of genomic instability and resulting huge number of other mutations characteristic 
of cancer cells [1]. As such, investigating the effects of alterations in these genes  is emerging as a 
crucial step on the path to unravelling the complex web that is carcinogenesis. 
Gene Expression Profiling in Cancers 
 Gene expression profiling, or transcriptional profiling, allows for determination of the 
number of mRNA transcripts of thousands of genes at one time. This yields the relative 
expression of these genes in the cells or tissues being studied. Some methods include 
microarray, RNA-Seq, and serial analysis of gene expression (SAGE). These methods have 
revolutionized the process of discovering altered epigenetic states associated with malignancy 
[8]. 
 As this thesis employs DNA microarray data, that method will be further discussed. This 
technique makes use of DNA oligonucleotide probes microscopically arrayed onto a glass chip. 
DNA is isolated from the tissues and/or conditions of interest and fluorescently labeled. When 
spotted onto the chip, tagged fragments hybridize to complementary cDNA probes. The chip is 
then analyzed for strength of fluorescence at each spot. Degree of fluorescence provides a 
quantitative measure of gene expression for the array of probes [10].  
 The information gleaned from gene expression profiling such as this can be used to 
discover groups of malignancies with similar gene expression patterns. Classifications derived in 
this way have so far proven to be the best predictors of clinical outcome [11]. They are also useful 
for the aim of identifying molecular “driver” alterations, which is one of the key aims of modern 
cancer research. 
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 Cancer classification currently relies primarily on the subjective interpretation of both 
clinical and histopathological information. Unfortunately, “there is a wide spectrum in cancer 
morphology and many tumors are atypical or lack morphologic features that are useful for 
differential diagnosis” [12, 13]. Tumors are also placed in currently accepted categories based on 
the tissue of origin of the tumor. Research suggests that tumors arising from the same tissues 
share many molecular characteristics, which lays the groundwork for development of reliable 
identification schemes based on gene expression. “Molecular diagnostics offer the promise of 
precise, objective, and systematic human cancer classification, but these tests are not widely 
applied because characteristic molecular markers for most solid tumors have yet to be 
identified” [15]. Therefore, gene expression profiling research is crucial to advancement of our 
fundamental understanding of cancer and our clinical practices regarding cancer. 
Gene Expression Profiling in Pediatric Ependymoma 
 This thesis will evaluate gene expression profiling data in the form of microarray analysis 
of 102 pediatric ependymoma (PE) tumors, collected as part of a multi-institutional effort to 
address some of the above outlined questions as they pertain to PE. 
 Gene expression profiling experiments require large sample sizes for their conclusions to 
be accurate or of any significance. Given the demonstrated importance of these experiments to 
furthering cancer research, it follows that large studies involving cooperation among several 
institutions such as this are also crucial. 
Until very recently, PE had been greatly understudied. Pediatric cancers are far more 
rare than cancers in adults (15 versus 460 per 100,000 respectively), and brain cancers in 
particular are overall more rare (account for 2% of cancer occurrences worldwide). On top of 
that, collecting samples of brain tumors is particularly invasive, so samples can only be collected 
from tumors being resected for treatment purposes unless the tumor cannot be removed 
without damaging critical parts of the brain or the patient is not well enough for open surgery 
[15, 16].  All of these factors have contributed to a lack of samples for study and acted as 
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deterrents to studying this cancer. As a further consequence of this dearth of samples and 
resulting lack of research interest, there is a relative deficiency of cell lines, xenografts, and 
animal models of the disease compared with other intracranial neoplasms, making it even more 
difficult to pursue other lines of inquiry.  
That is why efforts such as these are so important. They serve to stop the feedback loop 
that hinders critical research in serious but less common diseases.  Each institution contributes 
samples that would have held little promise for discovery in isolation but become crucial data 
points when in aggregate. The wealth of data that then results from these cooperative studies 
can be mined in countless different ways and provide the basis for a multitude of new 
hypotheses and lines of inquiry, resulting in many more novel discoveries than could have been 
made by one researcher or research group. Key molecular events in the pathogenesis of PE have 
yet to be defined, and research of this nature is key to kickstarting investigations due to its 
promise of substantial yield of novel hypotheses and discoveries. 
What is Pediatric Ependymoma? 
Ependymomas are primary tumors of the central nervous system that arise from the 
ependymal lining of the ventricular system. Pediatric ependymomas account for 10% of all 
pediatric brain tumors. They have a high propensity for recurrence, and current five-year 
survival rates range from 39% to 64%, with five-year event-free survival rates of 23% to 45% 
[17]. These tumors remain incurable in up to 45% of patients, with recurrent local relapse being 
the major cause of mortality[18, 19]. For reasons as yet unknown, ependymal tumors “manifest 
preferentially in childhood” [20].  
Currently, the most effective treatment is surgical resection, followed by radiotherapy. 
No chemotherapeutic regimens have thus far been shown to have any significant impact on 
survival [21]. However, over 50% of children whose tumors have been totally resected will still 
experience tumor recurrence despite aggressive adjuvant therapy [22]. Despite this, extent of 
surgical resection remains the only widely accepted prognostic factor of outcome [23]. 
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This suggests that the current understanding of this disease is lacking key insights into the 
driving mechanisms of this cancer, a concept that will be supported through further discussion 
of the current knowledge of PE.  
There are currently four major accepted histologic subtypes and three different World 
Health Organization (WHO) grades for PE. Two subtypes, called myxopapillary ependymoma 
and subependymoma, are classified as WHO grade 1. The histologically defined “ependymoma” 
subtype is classified as WHO grade 2, and the final histologic subtype, anaplastic ependymoma, 
is classified as WHO grade 3 [24]. Histology has been traditionally one of the primary methods 
for diagnosing and classifying ependymomas, as is true for most cancers. However, 
ependymomas are very heterogeneous tumors and recent research has found disparate mRNA 
expression profiles within these histologically-defined subtypes. [25]. Further, histological 
grading has proven to be a poor and unreliable predictor of outcome, illustrating the disconnect 
of diagnosis with prognosis using this method. [26]. These findings all support the hypothesis 
that the histological entity ‘‘ependymoma’’ in fact comprises a group of related diseases [27]. 
Tumor location is the other most traditionally employed diagnostic method. 
Classification of ependymomas by location employs a complicated nomenclature. They can be 
described broadly by their location as intracranial (inside the skull) or extracranial (outside the 
skull). They can also be described by their location within the CNS ventricular system. The two 
most common locations are supratentorial (cerebrum) and infratentorial (cerebellum). 
Infratentorial tumors are usually referred to as “posterior fossa” ependymomas. Less commonly, 
ependymomas can be found in the spinal cord and brainstem. Childhood ependymomas occur 
primarily in the posterior fossa region.  
Classification by location has still yielded somewhat more promising results than by 
histologic evaluation. Tumors from the same locations appear to have similar clusters of gene 
expression. Supratentorial tumors have been clustered into transcriptionally homogeneous 
subtypes, and some recent research has suggested possible expression-based subdivisions of 
posterior fossa tumors. However, these classifications still make the initial assumption of 
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dividing tumors by location. The large number of subtypes derived though these methods and 
the consistent heterogeneity in outcome and treatment response within them suggest that this 
also may not be the most effect approach to studying and classifying PE. 
To review, clinical behavior(s) within groups classified via these methods have proven to 
be highly variable. Outcomes can range from rapidly fatal to relatively slow-growing variants 
with instances of recurrence up to 20 years after initial treatment/presentation [28, 29, 30] 
These data show that there is currently a disconnect between diagnosis and prognosis in PE, and 
demonstrate that these two things must be aligned in order to do the most effective research and 
develop the most effective therapeutics for those suffering from this disease. Research presented 
in the previous section, “Gene Expression Profiling in Cancers”, shows that developing 
molecular-level expression-based diagnostics derived from expression analysis in accordance 
with prognosis will do that most effectively. 
While endeavors to this end have begun relatively recently, there are already some 
promising findings. Several genes have been identified whose altered expression levels seem to 
be effective predictors of poor prognosis. High expression of EGFR correlates with unfavorable 
outcome. Elevated expression of ERBB2, ERBB4 have been shown to promote tumor cell 
proliferation and predictive of poor prognosis [31]. Overexpression of TERT, the catalytic 
subunit of telomerase, and nucleolin, an interacting protein of telomerase, have been shown to 
be associated with increased tumorigenesis and increased tumor recurrence and predict a poor 
prognosis. IGF overexpression implicates deregulation of the sonic hedgehog (SHH) pathway 
which contributes to pathogenesis of PE [32]. Some molecular predictors of recurrence include 
overexpression of kinetochore proteins and underexpression of metallothioneins.  
In addition to furthering understanding of PE, results of this type also have the potential 
to be of broader applicability given the more fundamental nature of their findings. The purview 
of epigenetics in cancer and gene expression profiling is very broad, made only broader by 
discussion of their importance and applicability. This section has begun to narrow that scope by 
discussing the particular malignancy that will be the focus of this thesis, PE. In the following 
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sections, the scope will be further focused on the particular components of the gene expression 
machinery that will be addressed.  
  
Altered Chromatin States in Cancer 
 Further detail will now be given on this particular component of epigenetics. Histones, 
previously defined, function in mediating DNA compaction into chromatin. Depending on the 
array of coincident modifications on different histones in a given area, chromatin can be 
condensed (called “heterochromatin”) or relaxed (called “euchromatin”). These different states 
determine the accessibility of DNA to transcription factors and other DNA binding proteins. The 
modifications that result in these different states are mediated by histone modifying proteins. 
These include enzymes that are capable of acetylating or deacetylating, methylating or 
demethylating, phosphorylating or dephosphorylating, and adding or removing many more 
functional groups to or from histone proteins. Other types of proteins also play a role in 
determining chromatin state, such as those that bind to DNA at borders of heterochromatin and 
euchromatin and act as “insulators” against the spread of energetically/electrochemically 
favorable “spread” of modifications encouraging one chromatin state or the other [3, 6, 7]. 
  Alterations in any of these proteins can then have understandably broad and significant 
impacts on not just individual gene expression, but overall patterning of expression, genomic 
integrity, and chromosomal stability. It is becoming increasing clear that small alterations in the 
activity of one or a few of these proteins can lead to many of the hallmark genetic signatures of 
cancer, such as expression of oncogenes and silencing of tumor suppressor genes. This makes 
them promising candidates for being molecular “drivers” of carcinogenesis [33, 34]. 
 Alterations can result from native mutations in the gene encoding for a particular one of 
these proteins, or could be one of many results of initial failure of DNA repair mechanisms. They 
could also result from alterations in transcription factors necessary for their expression, whether 
genetic or epigenetic, which could result in their unnatural over or under expression.  
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Understanding the mechanisms underlying altered chromatin states is of increasing 
importance, as recent studies have demonstrated several histone modifying enzymes to be 
effective (relatively safe, easy to develop, with potent effect, fewer negative effects) drug targets 
[35, 36]. 
Altered Chromatin States in Pediatric Ependymoma 
 While high levels of variability are found across most cancers, ependymomas are 
particularly variable. At the level of cytogenetic analysis, about 50% of cases appear 
karyotypically normal, with other cases harboring an array of large chromosomal aberrations 
including monosomy 22, deletions of 22q, gains on 1q, gains on chromosome 7, and losses on 
6q, 9, and 13.  Those are the most frequently observed alterations and none of them are present 
in more than 30% of cases. This heterogeneity has also been observed in experiments beginning 
to look at gene expression in PE [21, 37-39]. This heterogeneity suggests a defect in maintenance 
of genomic stability could underlie the variability observed at these levels. This makes PE a good 
candidate for investigating potential driver mutations of proteins involved in regulation of 
chromatin state. Therefore, examination of altered chromatin states in PE has high potential of 
leading to a more fundamental and clinically pertinent understanding of its development and 
pathogenesis. 
Histone Modifying Enzyme SUV4-20H2 Effect on Chromatin State 
SUV4-20H2 is a histone methylating enzyme with specificity for lysine 20 on histone 
protein H4. SUV4-20H2 contains a SET domain which is responsible for its methyltransferase 
activity. Research has yielded conflicting findings regarding which methyl group this enzyme 
catalyzes the addition of. It is not responsible for the addition of the first, but functional studies 
have indicated that it is responsible for addition of the third methyl group [40] while structural 
studies have indicated that it is responsible for addition of the second and specifically not the 
third [41].  
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It is a homolog of the Drosophila protein Su(Var)4-20, which has known function in 
suppressing transposable elements near telomere ends. Unlike its relative in drosophila, this 
protein seems to function primarily  in pericentric heterochromatin regions, where it plays a 
central role in the establishment of constitutive heterochromatin. More broadly, trimethylation 
of histone H4 at lysine 20 has been shown to induce compaction of chromatin into 
heterochromatin and resultant gene silencing and dimethylation at this residue has been 
implicated to play a role in DNA repair. An increase in H4K20me3 with corresponding decrease 
in H4K20me1 has been shown to facilitate exit from cell cycle and initiation of differentiation. 
Altered expression of this protein has been found in lung cancer, colon cancer, and breast cancer 
[42]. Studies have yet to determine a broadly applicable role or specific mechanism of how 
altered expression of this protein is related to carcinogenesis. This thesis will present evidence in 
support of a possible model to this end.  
Summary 
As suggested throughout this introduction, the goal of this thesis is to contribute to the 
furthering of our understanding of the role of altered chromatin states in cancer and their 
potential as prognostic indicators by investigating patterns of altered gene expression in one 
type of cancer and beginning to elucidate the mechanisms that underlie them. Specifically, I 
sought to understand the negative correlation found between expression of SUV4-20H2, a 
histone modifying enzyme, that was found to have altered expression in a subset of pediatric 
ependymoma, and expression of tumorigenic genes. To do this, we have (1) characterized 
patterns of gene expression associated with disease subtypes, (2) evaluated the presence of those 
patterns in experimentally available samples, (3) developed a hypothesis regarding altered 
expression of the histone modifying enzyme SUV4-20H2, and (4) investigated the hypothesized 
interaction of this enzyme with tumorigenic genes of interest and the presence of its chromatin 
altering modifications near those same genes. Here, we confirm that expression of the histone 
modifying enzyme SUV4-20H2 is altered in a tumor subgroup specific manner correlated to 5-
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year and overall survival rates and that its expression is negatively correlated to expression of 
numerous proto-oncogenes. We then show that SUV4-20H2 binds near the promoter region of 
hTERT, one of said proto-oncogenes and a potent prognostic marker. Furthermore, our results 
demonstrate the presence of SUV4-20H2-catalyzed modifications near the promoter region of 
hTERT. Taken together, our results indicate a role for SUV4-20H2 in inhibiting tumorigenicity 
of tumor initiating cells in cancer. Finally, experiments in progress should reveal more about the 
nature of the altered chromatin state resulting from loss of SUV4-20H2 in tumors. 
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METHODS 
Analysis of microarray data 
Human exon microarrays using the Affymetrix Human Exon 1.0 ST Gene Chip system 
were run and results for 102 pediatric ependymomas were compiled. Only patients with WHO II 
and III grade ependymomas were analyzed in this study, while all other variants including 
subependymomas, ependymoblastomas, and myxopapillary ependymomas were excluded. The 
received file contained the gene signal data. Background correction and normalization had been 
performed following the PLIER method [Supplemental Material- 1] and core gene groupings 
were used for gene signal estimate. Probe sets were annotated according to the human genome 
build HG19 (GRCh37). An analysis pipeline was designed and applied to these data.  
The first step in the analysis pipeline was to “clean-up” the data. The expression values 
for each gene were normalized to the mean expression in controls (fetal non-cancerous brain 
tissue samples). Next, a variance filter for genes was applied to eliminate low informative genes 
from future analysis steps. Genes were ranked by expression variance across samples. The top 
1000 highest variance genes were kept on the working gene list [43] . 
Data were then classified into prognostic groups. Anonymous cohort data associated via 
sample ID with the assayed samples were accessed in a separate file. Necessary clinical data was 
available for 86 of the samples. Five-year progression free survival data was used for 
classification.  Samples were classified as poor prognosis (PP) if they did have progression 
within five years and good prognosis (GP) if they did not have progression within five years from 
resection.  
Overall differential gene expression between classified groups was then evaluated. This 
preliminary examination was conducted using a basic permutation test for large sample sets 
(Wilcoxon Signed Ranks test) using R language in RStudio [44]. The aim at this stage was only 
to determine the presence of overall differential expression and not generate a list of specific 
genes. A permutation test for two independent samples allows for comparison of the mean 
!16
scores for two independent sets of interval data. Therefore, this test was determined to be 
sufficiently stringent. It was hypothesized that there would be significant differences in gene 
expression associated with the “good prognosis” and “poor prognosis” classifiers. The null case 
was that differences in gene expression were not tied to these classifications. Conditions for 
rejection of the null hypothesis were determined based on the data set characteristics. The test 
statistic was computed for the data and random permutations. Formulas and calculations for 
rejection criteria, test statistics, and p-values can be found in Supplemental Material- 2. The 
calculated p-value describes the likelihood of the observed differences in gene expression 
occurring if they were not a result of the classification. This value was used to accept or reject the 
null hypothesis and thereby evaluate whether there was overall differential gene expression that 
could be attributed to the prognostic classifiers. 
The next aim was to identify biologically relevant genes with highly significant altered 
expression between the prognostic groups that could warrant further study. This was addressed 
in two steps: (1) determination of differential expression of sets of biologically-related genes, 
followed by (2) identification of the genes within those groups that demonstrate the most most 
significantly altered expression. The first step was conducted using MSigDB Canonical 
Pathways for gene set analysis using the method described by Subramanian et.al. 
[Supplemental Material- 3], which will be subsequently referred to as GSEA [45].  The gene sets 
determined in that step were then further analyzed to determine which genes within those 
groups showed the greatest differential expression. The significance analysis for microarrays test 
( SAM), as developed by Tusher et.al. at Stanford University [Supplemental Material – 4] was 
applied to the list of genes derived from the gene set analysis [46]. Briefly, gene-specific 
permutation analysis was conducted and the ranked observed z-values were compared to the 
total gene permutation distribution. This distinction results in output of genes that are 
significantly differentially expressed as compared to the null hypothesis and each other. For 
further analysis following GSEA, a non-parametric approach such as this was necessary given 
the inherent correlations in the expression of the resulting genes. Also, this methodology of 
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gene-specific analysis is optimized for minimizing both type one and two error. Further, this is 
one of the few methods of microarray analysis that has achieved some degree of widespread use 
and consensus [47].  
The resulting lists of over expressed and under expressed genes were analyzed with 
literature review and against other collected data.  
Real-time PCR for validation of microarray data 
 Primers were designed using NCBI’s “Primer-Blast” platform, a combination of 
“Primer3” and “BLAST”. Primers and description of specifications used for primer design can be 
found in Supplemental Material-9. Primers were designed to be targeted to exons of 
SUV4-20H2, TERT, and the endogenous control, cyclophilin A (PPIA).  Specific regions were 
selected based on three criteria: (1) being within 500 bp of the 3’ end of the coding region, (2) 
75-150 bp amplicon, and (3) splice-invariant amplification. Those are consensus qualifications 
for primers to be used with SYBR Green chemistry. A fourth qualification was necessary for 
comparison between microarray and qPCR assays and the following; primers had to be designed 
for exonic regions.  
 Newly designed primers as well as previously-developed primers (ERBB2, ESCO2, 
IGF-2) were optimized for concentration using VC-1629 cDNA (normal brain control). Stepwise 
concentrations of 0.5x, 1.0x, and 1.5x were used against template test concentrations of 4x, 2x, 
1x, 0.5x, and 0.25x with constant 1x Power SYBR Green PCR Master Mix [2x]  in 10µl reactions. 
Reactions were run on an Agilent Mx3005P qPCR System. Cycling conditions (standard SYBR 
Green conditions, same as below) were kept constant with the exception of annealing 
temperature, which was altered based on the melt temperature of the primer in question. 
 RNA extracted from PE samples from the VCU Neurosurgery Brain Tissue Bank was 
analyzed with an RNA Pico chip on an Agilent 2100 Bioanalyzer to assess RNA quality and 
concentration (standard protocol, Supplemental Material-5). 
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Two-Step RT-PCR was performed on the selected tumor samples. SABosciences RT2 kit 
reagents were used. Reactions were set up with 2µl gDNA buffer, volume necessary for 1µg RNA 
from respective tumor samples, and remaining nuclease-free H20 to 14µl. These reactions were 
denatured in a thermal cycler for 2 minutes at 42℃. Following denaturation, 1µl RT2 Master 
Mix, 4µl RT buffer, and 1µl RT primer were added to each reaction tube. Reactions were then 
incubated for 15 minutes at 42℃ followed by 3 minutes at 95℃. Concentration of cDNAs was 
evaluated on a NanoDrop instrument using standard protocol [Supplemental Material-6]. 
 VC-1629, a normal brain-derived cell line, was used as the positive control in these 
experiments. Sybr Green chemistry was used for qPCR, with the Power SYBR Green PCR 
Master Mix [2x]. The reference gene used was cyclophilin A (PPIA). For each primer set, 
reactions were run in triplicate with a nuclease-free H2O no template control, each of the 14 
tumor samples, and the NT2 positive control. 20µL reactions were run with respective 
optimized primer concentrations, volume of sample equivalent to 10 ng, 10µL master mix, and 
remainder to 20µL of nuclease-free H2O. Cycling conditions were run as specified by the 
chemistry. 10 minutes at 95℃ for enzyme activation was followed by 40 cycles of 15 seconds at 
95℃ followed by 60 seconds at the primer-specific anneal and extend temperature.  
Analysis of real-time PCR data 
 Mean cycle threshold values were collected for each set of primer-target triplicate wells. 
Results were then normalized and analyzed using the 2(-𝚫𝚫Ct)  method. 𝚫𝚫Ct was calculated as 
follows:    
ΔΔCT=(CT(target,NT2)−CT(RPL30,NT2))- (CT(target,tumor)−CT(RPL30,tumor)) 
P-values were calculated using the mean values of each set of tumor subtypes compared 
to the control using the reference normalized values, CT(target,NT2)−CT(RPL30,NT2) and 
CT(target,tumor)−CT(RPL30,tumor). These calculations were done for each of the genes of interest. 
!19
The 2(-𝚫𝚫Ct) was also calculated from the mean ΔΔCT values. Those values were then Log2 
transformed so that underexpression and overexpression values could be better understood in 
direct comparison. These calculations yielded values for Log2 transformed fold-change relative 
to  control. 
 To compare these results to the microarray results and validate that the same altered 
expression is found in each subset of samples, Pearson’s correlations were calculated (in 
RStudio) between the microarray and qPCR fold change values and values were plotted against 
each other for visualization of the comparison.  
     
Chromatin Immunoprecipitation 
 Flash frozen tumor samples VC-273, VC-300, VC-78, and VC-1266 were extracted from 
the -80℃ freezer they had been stored in since their collection. They were quickly thawed at 
room temperature. 1x1 mm chunks were resected from the samples and placed in 15 ml tubes. 
Tumors were immediately placed back into storage in the -80℃ freezer. Based on prior 
experimentation, 1x1 mm of this type of tissue was established to be approximately 50 ng. While 
estimation is never desirable, higher levels of precision in this case would have necessitated 
more interaction with the tumor sample and therefore more possibilities for contamination or 
degradation. Given the extremely limited amount of these tissues and the importance of future 
experimentation, estimation is preferred.  
5 ml of 1% formaldehyde cross-linking solution was prepared by adding 143 µl of 35% 
formaldehyde solution to 5 ml cell culture medium. 1 ml of cross-linking solution was added to 
each of the four tubes containing tumor sample (1 ml per 50 ng tissue). Tubes were then 
incubated at room temperature on a rocking platform for 20 minutes. 111 µl 1.25M glycine was 
then added to each tube (1 ml 1.25M glycine per 9 ml cross-link solution). Reactions were mixed 
by flicking then centrifuged at 800 rpm for 5 minutes at room temperature. Supernatant was 
discarded by pipetting, as cross-linked cells formed no cohesive pellet from which the 
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supernatant could be easily poured off. Cells were then washed with 10 µl PBS solution that had 
been kept on ice by spinning again at 800 rpm for 5 minutes, and supernatant was again 
discarded by the same method. 
Reagents used for subsequent steps of chromatin extraction came from Epigentek. 
Working lysis buffer was prepared by adding 1.5 µl protease inhibitor cocktail to 3 ml lysis buffer 
(ratio of 6 µl protease inhibitor cocktail per 10 ml lysis buffer recommended by kit protocol). 
500 µl (0.5 ml per 50 ng tissue) was then added to each of the four tumor samples. Tissue was 
homogenized in solution using a dounce homogenizer. Solutions were then transferred to 2 ml 
microcentrifuge tubes and spun at 3000 rpm for 5 minutes at 4℃. Following centrifugation, 
supernatant was discarded, leaving the pellet containing the chromatin in the tube. 100 µl of 
ChIP buffer (100 µl per 50 ng tissue recommended) was added to each of the four tubes. Lysate 
was then incubated on ice for 10 minutes. Lysate was then resuspended by brief vortexing. 
Chromatin was then sheared by sonication. Sonicator was set to 25% power and samples were 
rotated through four 10s pulses and left on ice between pulses. Sonicator power level, time per 
cycle,  and number of cycles was previously optimized for these sample types, so again although 
some degree of error could have been introduced here, it was necessary to preserve sample. 
Following sonication, samples were centrifuged at 12,000 rpm for 10 minutes at 4℃. 
Supernatant containing chromatin was then removed and transferred to a new 1.5 µl vial. 
 Antibodies against the SUV4-20H2 enzyme, and the modified proteins that result from 
its action, H4K20me2 and H4K20me3. The H4K20me2 and me3 antibodies were ChIP-
validated from  AbCam. The SUV4-20H2 antibody was from ActiveMotif. Positive and negative 
control antibodies against RNA polymerase II and non-immune IgG respectively were also from 
the Epigentek Chromatin IP kit. To ensure the efficacy of the antibodies and the 
immunoprecipitation protocol , preliminary chromatin immunoprecipitation was performed on 
just NT2 chromatin. 
 First, antibodies were bound to the provided reaction wells (strip wells provided in kit). 
The concentration of the SUV4-20H2 antibody was 0.25 mg/ml and the H4K20me2/3 and 
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control antibodies were of concentration 1 mg/ml. 0.8 µg were needed for the antibody binding 
reaction, so 3.2 µl SUV4-20H2 antibody and 0.8 µl H4K20me2/3 and control antibodies were 
added to individual wells. 80 µl Antibody Buffer was also added to each well. Then wells were 
incubated at room temperature on an orbital shaker at 100 rpm for 90 minutes. The antibody 
reaction solution was then removed from the wells and they were washed with 150 µl ChIP 
buffer. ChIP reactions were then assembled in the antibody-bound wells. Volume of chromatin 
sample added to each well was calculated to be equivalent to 2 µg per well. Volume of ChIP 
buffer was added to final volume of 90 µl (exact volumes used can be found in Supplementary 
Material-7). 10 µl of blocker solution was also added. Wells were capped and incubated at room 
temperature for 90 minutes on an orbital shaker at 100 rpm. Following incubation, reaction 
solution was pipetted out and discarded. Wells were washed with 200 µl wash buffer 4 times, 
with 2 minutes on an orbital shaker at 100 rpm between each wash. Wells were washed one time 
with DNA-release buffer (DRB) by pipetting it in and out. 40 µl DRB-RNase A was added to 
each well. Wells were then incubated at 42℃ for 30 minutes. 2 µl of Proteinase K was then 
added to each well, followed by incubation at 60℃ for 30 minutes. The DNA solution from each 
well was transferred to 0.2 ml strip PCR tubes, which were then incubated at 95°C for 15 min in 
a thermocycler. Tubes were spun briefly and 200 µl DNA binding solution (DBS) was added. 
Solution was then transferred to a spin column in a 2 ml collection tube and centrifuged at 
12,000 rpm for 30 seconds. Columns were washed with 200 µl of 90% ethanol, then centrifuged 
again at 12,000 rpm for 30 seconds. Flow-through was discarded, and wash was repeated two 
more times. Columns were placed in new 1.5 µl vials and 11 µl of DNA elution buffer directly to 
the filter in the column and centrifuged at 12,000 rpm for 30 seconds to elute purified DNA.  
 Gel electrophoresis was used to evaluate the results of the ChIP pulldown. A 1.2% gel was 
made using .6 grams of agarose to 50 ml of 1x TAE running buffer. A 5x loading buffer was used, 
with a prepared mix of 1 µl of loading buffer and 4 µl of the sample. A GelDoc imager was used 
to visualize the results. 
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After the antibodies and chromatin immunoprecipitation protocol were validated, 
immunoprecipitation was performed on the chromatin extracted from the tumors and NT2 
chromatin using the above procedure. 
Real-time PCR of ChIP pulldowns and Analysis 
 qPCR was performed using the same general procedure as above. Differences included 
the primers were instead designed against promoters for this assay as that is the region of 
interest for chromatin modifications or SUV4-20H2 binding. Two sites  in particular in the 
TERT promoter were targeted bisulfite microarray results that indicated CpG islands in these 
regions, which suggests them as site of regulatory control.  No reference genes were used, but 
input control (1%; DF = 6.644) and negative control (Ab-IgG) pulldowns for each sample were 
run in addition to the test antibody pulldowns. 
 Mean cycle threshold values were collected for each set of primer-target triplicate wells. 
Ct values were normalized to assay background by subtracting input-normalized negative 
control Ct values from respective input-normalized test antibody Ct values. 2(-𝚫𝚫Ct) was 
calculated from those normalized values. Log2(2(-𝚫𝚫Ct)) was calculated for comparability and 
graphical visualization.  
ChIP-sequencing 
 Chromatin immunoprecipitation was performed according to the same protocol as 
above. Following ChIP, DNA quality and concentrations were determined using a 
ThermoScientific NanoDrop instrument following standard protocol [Supplementary 
Material-6]. Then ChIPed DNA library was prepared. Reagents for library preparation came 
from Epigentek EpiNext ChIP-Seq High-Sensitivity Kit.  
Reactions were set up for DNA end polishing with 10 µl ChIPed DNA , 1.5 µl 10x end 
polishing buffer, 1 µl end polishing enzyme mix, 1 µl end polishing enhancer, and 1.5 µl distilled 
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H2O. Reaction was incubated in a thermocycler (no heated lid) at 25°C for 20 minutes followed 
by 20 minutes at 72°C. Adaptor ligation reactions were then set up with 15 µl end-polished DNA, 
17 µl 2x ligation buffer, 1 µl T4 DNA ligase, and 1 µl of adaptors. Reactions were incubated for 15 
minutes at 25°C.   
Clean-up of the adaptor-ligated DNA was then performed as opposed to size selection 
due to low concentration.  34 µl of resuspended MQ Binding Beads were added to the PCR tube 
from that reaction. Tubes were then incubated for 5 minutes at room temperature to allow DNA 
to bind to beads. Tubes were then placed in a magnetic stand for 3 minutes (or until solution 
was clear). Supernatant was removed and discarded with care not to disturb the beads, to which 
the DNA was bound. Beads were then washed three times with 200 µl of freshly prepared 90% 
ethanol (incubated at room temperature for 1 min with each wash). Tubes were then left open 
for 10 minutes in the magnetic stand so that beads could air dry. Beads were then resuspended 
in 12 µl Elution Buffer and incubated at room temperature for 2 minutes to release the DNA 
from the beads. Tubes were placed in the magnetic stand once more for 4 minutes (or until 
clear), and 11 µl of supernatant was extracted carefully by pipet and transferred to a new 0.2 ml 
PCR tube for PCR amplification. 
Following clean-up, library amplification reaction was set up. 10.5 µl adaptor ligated 
DNA from each sample-antibody reaction was added to 12.5 µl 2x Hifi master mix and 1 µl each 
of primer U and primer I. Reactions were cycled for 30 seconds at 98°C, 15 cycles (calculated 
based on concentration of DNA) of 20 seconds at 98°C, 20 seconds at 55°C, and 20 seconds at 
72°C, followed by a final 2 minutes at 72°C. 
Clean-up was conducted again following the same procedure. 
Resulting DNA solutions were diluted 5-fold with H2O and run on an Agilent 
Bioanalyzer with the DNA High-Sensitivity kit, following provided protocol (Supplementary 
Material-5). The purpose of this was to evaluate the size distribution of DNA fragments and 
determine if there are any contaminants.   
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Size selection was then conducted due to presence of adaptor contaminant in prepared 
library. Size selection follows approximately the same procedure as clean-up with the exception 
of the very first step. For size selection,  only 14 µl of resuspended MQ Binding Beads were 
initially added to the PCR tube containing the DNA. Tubes were then incubated for 5 minutes at 
room temperature to allow DNA to bind to beads and subsequently placed in a magnetic stand 
for 3 minutes (or until solution was clear). Following this, the supernatant which still contained 
some DNA was transferred to a new tube and the beads containing the unwanted DNA were 
discarded. Then, 10 µl of beads were added to the new DNA-containing solution and the 
subsequent procedure matches that of clean-up. 
Samples were again analyzed on the bioanalyzer and subsequently run through 




Pediatric ependymoma subtypes display significantly altered patterns of gene 
expression 
This analysis sought to investigate potential underlying mechanisms and driving 
mutations of carcinogenesis by identifying relevant subtypes and then “discovering” the gene 
expression profiles associated with them. With this approach, the particular aspects of gene 
expression that underlie a resultant phenotype can be more directly targeted. This investigation 
was carried out using microarray data acquired from NCBI’s Gene Expression Omnibus 
database. The corrected and normalized expression data were (1) filtered for variance, (2) 
classified into prognostically-defined subtypes, and (3) evaluated for associated differential gene 
expression. After completion of these steps, patterns of altered gene expression were further 
probed for alterations associated with epigenetic dysregulation.  
The gene expression profiling data used in this analysis result from an Affymetrix 
Human Exon 1.0 ST GeneChip microarray. As described previously, this profiling was 
conducted using 102 pediatric ependymomas. The data sets used in this analysis were already 
background corrected and normalized by the PLIER method [Supplemental Material – 1] the 
gene signals were already estimated using core gene groupings when it was received. The PLIER 
method was developed by Affymetrix specifically for this purpose. As such, it is the most widely 
used method and appears to provide the most accurate gene expression value of available 
platforms. Therefore, error is minimized and consistent with field standards going into analysis. 
The full files like the ones used here contain large quantities of data; in this case, 102 
samples on arrays capable of measuring expression of upwards of 17,000 well-annotated gene 
transcripts (22,178 in this case). As such, attempts at analysis require large amounts of time and 
powerful computing. However, there is not a constant ratio of data to information yield. To 
address this, a variance filter was applied for genes across all of the samples. The aim was to 
!26
eliminate low informative genes (i.e. genes that were fairly constant across all samples) from 
future rounds of analysis. With the variance filter set to keep only the top 1000 of the variance-
ranked genes, this step resulted in a far more manageable and powerful gene list for subsequent 
analysis. A review of recent literature suggests this as an emerging consensus first step in the 
analysis pipeline for gene expression profiling [48]. 
The next aim was to distinguish patterns of gene expression associated with prognosis. 
As outline above, we determined to classify the tumor samples by prognosis first and 
subsequently compare their expression patterns. This approach was decided upon after 
extensive literature review of genetic profiling experiments in PE and related cancers.  
Five year progression-free survival data was used to determine prognostic class. This 
data was available for 86 samples. Of those, 32 samples were classified as good prognosis (GP), 
and 54 samples were classified as poor prognosis (PP).  
We then used the Wilcoxon signed-ranks test [Supplemental Material-2] to evaluate the 
differential expression between these groups. With this, we find significantly distinct patterns of 
gene expression are associated with the good prognosis and poor prognosis groups (Fig. 2). 
These findings demonstrate the validity of these prognostic classifiers for isolating molecularly 
distinct subgroups and confirm that further study is warranted. 
Poor prognosis subgroup shows altered expression of genes related to cell cycle 
regulation, tumor suppression, and DNA replication and repair 
Having established that differential expression is associated with prognosis, we next 
sought to further investigate this altered expression with a focus on genes related to epigenetic 
dysregulation, particularly in the poor prognosis class.  These are the tumors with fewer gene-
level aberrations and a higher likelihood of recurrence, and therefore more likely to have 
“driver” alterations in expression of critical components of the epigenetic machinery. To do this, 
we (1) performed gene set analysis to identify cellular functions most impacted by altered 
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expression and then (2) conducted significance analysis for microarrays (SAM) to identify 
particular genes driving those perturbations. 
These assays were chosen over others for several reasons. First, this method has been 
found to show much more cross-study concordance than single gene methods. While there have 
been several recent projects aimed at standardizing gene-specific analysis techniques, 
comparisons among different studies and different statistical tests continue to show an alarming 
lack of concordance [49, 50]. Second, GSEA can better detect differential expression of low 
expressed but biologically relevant genes that might get passed-over by the stringent 
significance levels employed in individual gene methods. Finally, our interest in altered 
regulation of key functional sets of genes and the potential “driver” alterations within them 
supported the use of GSEA followed by SAM. 
 Gene set analysis was conducted using the normalized, variance-filtered gene list.  As 
described in the methods, the GSEA platform and associated gene lists were employed for this 
analysis. Results show that in this subgroup of PE, there are significant perturbations in the 
gene sets associated with cell cycle, tumor suppression, and DNA replication and repair. 
To identify the particular genes that may be driving those perturbations, we sought to 
find the genes within those gene sets with the most significantly altered expression.  The 
statistical analysis for microarrays (SAM) test was used to do this. Through this analysis, a short 
list of the most significantly overexpressed and underexpressed genes in this subgroup was 
generated (Fig. 3C).  
Results were first screened for epigenetic regulatory components. We find that 
SUV4-20H2, a histone modifying protein, is underexpressed in this subtype of pediatric 
ependymoma (Fig. 3). This result is supported by preliminary evidence from our lab indicating 
focal loss of chromosome 19 in a subset pediatric ependymoma, and suggests that further 
experimentation should be conducted to evaluate the distribution of this observation according 
to the prognostic classifiers used in this analysis. Results of such a study could provide valuable 
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support or concerns for the findings from this analysis. These factors support SUV4-20H2 as a 
gene of interest for further experimentation.  
Inspection of the list of overexpressed genes reveals several candidate proto-oncogenes 
(genes which, when overexpressed, lead to carcinogenesis). Within our list of overexpressed 
genes we find TERT and ErbB2, as expected (Fig 3). Overexpression of each of these genes has 
been indicated to correlate with poor prognosis in other studies. Previous research has 
suggested a possible negative correlation between expression of TERT and SUV4-20H2, so these 
findings provide further support to each other. We also find IGF-2 to be overexpressed. IGF-2 
was shown to be elevated in ependymoma in another microarray experiment [54] and has 
previously shown to play a role in tumorigenesis in numerous other cancers [55], most likely due 
to it’s role in AKT signaling. Finally, ESCO2 is found to be overexpressed. ESCO2 
overexpression in PE has been demonstrated in other experimentation by this lab investigating 
its potential role in a PE pathogenesis. This, in addition to the cross validation of overexpression 
of ESCO2 in PE, support its inclusion in further analysis.  
These data, in conjunction with other findings regarding the general function of 
SUV4-20H2 (discussed in Introduction: Histone Modifying Enzyme SUV4-20H2 Effect on 
Chromatin State), support a model wherein loss of SUV4-20H2 leads to loss of heterochromatin 
surrounding these proto-oncogenes which, in turn, leads to their overexpression and cancer 
progression (Fig. 4).  
Altered expression levels observed in microarray data also observed in VCU 
subset of pediatric ependymomas 
For reasons addressed previously, only a limited number of samples were available for 
functional assay in our lab. Given the small population, it was particularly necessary to confirm 
the expression changes of interest in these samples before proceeding to further assessment. 
This also served as cross-validation with the microarray results. Therefore, the relative 
expression levels of the proto-oncogenes identified above (TERT, ERBB2, ESCO2, and IGF-2), 
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were assessed in the VCU cohort of pediatric ependymomas. To test this, two-step RT-qPCR was 
employed.  
While information derived from genomic analysis is for the most part static and context-
independent, information gleaned from analysis of the “transcriptome” (i.e. microarray and 
qPCR) is inherently variable and context-dependent. This results from varying levels of mRNA 
transcripts and complementation being associated with several dynamic factors including 
physiology, pathology, and development. As such, several components of our assay had to be 
optimized to ensure reliability and reproducibility of results. These include: (1) assessment of 
RNA quality and (2) PCR primer design and optimization.    
First, RNA quality was assessed. This is a necessary step as RNA is unstable and prone to 
degradation once removed from its cellular environment. A recent review of RT-qPCR practices 
argues that the quality of the template is the most important determinant of the reproducibility 
and biological relevance of subsequent qRT-PCR results [51]. RNA quality and concentration 
was evaluated in PE samples from the VCU Neurosurgery Tissue Bank. Some of the samples 
investigated were of relatively good quality, while others clearly showed some degradation. The 
eleven samples selected were not in perfect condition, but given the lack of sample availability, 
standards had to be lowered below ideal. Extent of degradation in the samples was recorded and 
associated with the samples throughout subsequent analysis to account for error. 
We next designed primers for SUV4-20H2, TERT, and the reference gene PPIA as 
detailed in the methods section. Design of primers for RT-qPCR is critical for amplification of 
intended specific gene products. The primers we generated are found in Table 2. We then 
validated and optimized these, as well as previously-designed primers (ERBB2, ESCO2, IGF-2; 
same considerations for design) using stock cDNA of VC-1629 (normal brain control). Through 
successive rounds of optimization, we found ideal concentrations and annealing temperatures 
for these primers on the machine and with the chemistry we were using. The final primer stocks 
run under these conditions were uncontaminated, efficient and did not dimerize (data not 
shown). 
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Having satisfied the necessary preparatory steps, expression levels of our genes of 
interest could be evaluated. Specifically, two-Step RT-PCR was performed on the eleven tumor 
RNA extracts. Reverse transcription was carried out according to the described methodology 
and the resulting cDNAs were evaluated on a NanoDrop instrument. Optimized protocol 
eventually resulted in pure, uncontaminated cDNA pools of varying but sufficient concentration 
in the eleven samples (data not shown).  The resulting cDNA was then used to set up the 
reactions for the qPCR. Sybr Green chemistry was used for qPCR, with the Power SYBR Green 
PCR Master Mix [2x]. Each primer set was reacted with each of the eleven tumor samples, an 
H2O no template control (NTC), and a positive control. 
The raw “cycle threshold” values output from qPCR are the points at which fluorescence 
signal significantly exceeds background signal. The means of those values for each set of primer-
sample triplicates is calculated and used for normalization and subsequent calculations of fold 
change and significance. 
Our data show significant SUV4-20H2 down-regulation in tumors (Fig. 5A). We also find 
corresponding significant up-regulation of TERT, ERBB2, ESCO2, and IGF-2 (Fig. 5B-E). Upon 
qualitative examination of these data, they clearly exhibit the pattern of expression suggested by 
the microarray analysis. Given the known limitations of microarray analysis, it was still 
necessary to quantitate these results and assess the significance of their similarity. Pearson’s 
correlations were computed for the microarray versus qPCR fold changes at each gene. This 
analysis finds significant correlation of the relative expression of SUV4-20H2 and all four proto-
oncogenes between the microarray and qPCR data (Fig. 6). Correlation is the most effective 
measurement for comparing data across platforms in this way.  
 SUV4-20H2 binds to chromatin near TERT promoter 
The previous assay served to demonstrate significant alterations of gene expression in 
our sample population, a necessary prerequisite to investigation of the following aims. Given the 
normal repressive function of SUV4-20H2, the observed correlation between decreased 
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expression of SUV4-20H2 and overexpression of key proto-oncogenes may be reflective of an 
underlying functional mechanism. Therefore, we next sought to determine if SUV4-20H2 acts 
directly to regulate the proto-oncogenes of interest (TERT, ERBB2, ESCO2, and IGF-2).  To do 
this, chromatin immunoprecipitation (ChIP) was performed to assess SUV4-20H2 binding to 
chromatin near the promoter regions of our target genes. ChIP was performed on the four 
samples selected for their high quality using a 1°anti-rabbit SUV4-20H2 antibody. Although our 
antibodies were ChIP-quality verified, the low availability of these tissues necessitates stringent 
validation prior to every assay in which they are used. Their efficacy was validated on our NT2 
cell line. Results confirmed their efficacy (Fig. 7A). 
To quantify our results, qPCR was performed on the pools of DNA pulled-down DNA 
through ChIP. This required development of new primers for the proto-oncogenes, as detection 
of a different region of these genes was desired as compared to the previous qPCR experiment. 
These experiments sought to evaluate a potential direct regulatory role of SUV4-20H2 on our 
genes of interest. SUV4-20H2 tends to be found associated with areas of DNA methylation and 
promoters (Fig. 8).  Therefore, quantification of binding near the 5' ends of the promoters (or 
even more specific regulatory sites if known, i.e. TERT) of these genes was sought and primers 
were designed accordingly.   
Results of these qPCR show that SUV4-20H2 binds near the promoter of the TERT gene 
in both neurally restricted cell lines and in PE tumor samples (Fig. 9). Reflective of the implied 
decreased concentration of SUV4-20H2 proteins in the cancer cells, significantly less TERT was 
detected in the tumor-derived DNA pools (Fig. 9, Table 1). It is important to highlight that 
SUV4-20H2 was also shown to occupy chromatin near the TERT promoter in the normal 
control, as this supports a normal state in which SUV4-20H2 serves to effectively silence the 
TERT gene. These results support the hypothesis that aberrant loss of SUV4-20H2 in these 
tumors leads to decreased chromatin compaction surrounding proto-oncogenes and their 
resultant increased expression. 
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Results for the other three proto-oncogenes, however, indicate that SUV4-20H2 does not 
bind near their promoter regions. More specifically, DNA levels in SUV4-20H2 pulldowns were 
not detected to be significantly above those in the negative control (anti-IgG) (Table 3). This 
could be due to a number of different factors, the most obvious being that SUV4-20H2 simply 
does not directly regulate these genes. Alternatively, our primers may not have been in close 
enough proximity to where SUV4-20H2 binds to regulate them. This is a strong possibility, as 
there was no equivalent bisulfite analysis in these three genes to isolate the exact regulatory 
regions as there was for TERT. This could be addressed in future research by using several 
primers covering disparate regions of each gene. This coverage issue is addressed as a 
component of ChIP-sequencing experimentation in progress. Finally, these findings could result 
from SUV4-20H2 not being active at those genes at the particular time these samples were 
collected but could exert effects at other time points. This question will be addressed further in 
the next section.  
H4K20me2 and H4K20me3 modifications are present in chromatin near TERT 
promoter 
In addition to evaluating the presence of the actual SUV4-20H2 enzyme at proto-
oncogenes under investigation, we sought to determine whether the marks it confers were 
present near the promoter regions of these genes. This was necessary to control for the time-
dependent error associated with assaying for localization of the actual enzyme, as discussed in 
the previous section.  Specifically, we assessed whether H4K20me2 and/or H4K20me3 modified 
histones were associated with chromatin near the promoter regions of the proto-oncogenes. To 
do so, ChIP was performed on the four samples for which acceptable material for this assay 
could be obtained using  1°anti-rab H4K20me2 and 1°anti-rab H4K20me3 antibodies. Again, 
although our antibodies were ChIP-quality verified, the low availability of these tissues 
necessitates stringent validation prior to every assay in which they are used. Their efficacy was 
validated on our NT2 cell line. Results confirmed their efficacy (Fig. 7B and C). 
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qPCR was again employed to quantitatively evaluate the outcome of the chromatin 
immunoprecipitations, using the same primers as above. As we were interested in evaluating the 
potential regulatory role of SUV4-20H2-generated modifications on proto-oncogenes of 
interest, a first line of assays was to assess for these marks near likely regions of regulatory 
control. 
Consistent with previously discussed findings, results here indicate presence of 
H4K20me2 and H4K20me3 near the promoter of the TERT gene in both normal neurally 
restricted cell lines and in tumor samples (Fig. 10). Again, consistent with a decreased 
concentration of SUV4-20H2 proteins in the cancer cells, significantly fewer copies of the TERT 
gene were detected in the tumor-derived DNA pools than the controls (Tables 4 and 5). These 
results lend further support the hypothesized model.  
Comparably to what was observed above, DNA levels in the H4K20me2 and H4K20me3 
pulldowns for the remaining three genes were not detected to be significantly above those in the 
negative control (anti-IgG) pulldowns (Tables 2 and 3). These results taken alone could be 
attributed to some of the same potential errors as those from the SUV4-20H2 pulldown. 
However, when combined, all of these results support each other which indicates that 
SUV4-20H2 may not regulate these genes in particular.  
The opposite is true of the TERT findings in combination. These findings support each 
other and together provide strong support for a model in which SUV4-20H2 normally regulates 
the silencing of the TERT gene and its aberrant loss in these tumors leads to TERT 
overexpression.  
ChIP-Sequencing Experiments 
These findings alone provide strong evidence for a role for SUV4-20H2 in regulating a 
key tumorigenic gene, TERT. They also justify further investigation of the potential fundamental 
role of SUV4-20H2 in carcinogenesis. Although direct interactions were not observed in the 
previous assays for the other three selected proto-oncogenes, this could have resulted from 
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limitations on our experiments and do not necessarily support or detract from this hypothesis. 
Further experimentation to this end would have the aims of (1) determining which , if any, other 
proto-oncogenes SUV4-20H2 binds in proximity to, (2) evaluating the overall binding patterns 
of SUV4-20H2, (3) determining which, if any, other proto-oncogenes harbor H4K20me2 and/or 
H4K20me3 modifications, and (4) evaluating the overall patterning of H4K20me2 and 
H4K20me3 in pediatric ependymomas as compared to normal controls.  
To address these aims, it was necessary to again conduct ChIP in the same manner as 
above. This assay differs in the method of measurement. In this case, resulting pools are 
evaluated via next-generation sequencing to get the desired broader portrait of SUV4-20H2 
behavior. The chromatin immunoprecipitation would, as before, serve to isolate DNA fragments 
in regions of chromatin where these modifications are present or where SUV4-20H2 is bound. 
By evaluating these pools with sequencing rather than qPCR, the limitations imposed by the 
necessity of primers and corresponding specific hypotheses would be removed in place of a 
“screen” approach. 
Several attempts were made at this assay. However, issues occurred with library 
preparation. There is substantial risk associated with performing size selection on lower-yield 
pulldowns, so it was initially avoided in favor of an extra round of clean-up. However, 
Bioanalyzer analysis detected the presence of a large quantity of adaptors in the sample pools, 
and size selection was then deemed necessary. There then remained the risk of too little sample 
being left for analysis. Bioanalyzer analysis subsequent to size selection demonstrated the 
removal of the adaptors and the associated narrowing of the distribution of DNA fragments. 
This, in addition to other smaller issues, led to an extensive optimization period for this assay. 
Brain tissue is very heterogeneous and very limited quantities of good quality sample are 
available, both of which facilitate these poor results. Another attempt is currently in progress, 
but results were not available in time to be incorporated into this thesis. 
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DISCUSSION 
 The goal of this thesis was to contribute to the furthering of our understanding of the 
role of altered chromatin states in cancer and their potential as prognostic indicators by 
investigating patterns of altered gene expression in one type of cancer and beginning to 
elucidate the mechanisms that underlie them. Specifically, I investigated the histone modifying 
enzyme SUV4-20H2 and its role in a recurrent phenotype of pediatric ependymoma. 
 Our data indicate that the histone modifying enzyme SUV4-20H2 plays a role in 
regulating expression of TERT, the catalytic subunit of telomerase. We found that SUV4-20H2 
interacts with the promoter of TERT and that the modifications it imposes (H4K20me2 and 
H4K20me3) are present there.  The TERT promoter primers used to assay this were specifically 
designed for an area of the promoter shown to be rich in CpG residues and corresponding DNA 
methylation. These data together demonstrate that SUV4-20H2 interacts with the TERT 
promoter at a known site of DNA methylation and catalyzes the addition of methyl groups to the 
20th lysine residue on H4 histones in the surrounding area. 
 That area of the TERT promoter was selected as a region of interest in accordance with 
the current understanding of SUV4-20H2 mechanisms of localization.  SUV4-20H2 seems to be 
recruited to it’s site of action through interactions with components of DNA methylation 
machinery [40]. Promoter DNA methylation, as discussed in the introduction, serves primarily 
to silence the associated gene.  The modifications imparted by SUV4-20H2 promote chromatin 
compaction, which also leads to gene silencing [40].  
 TERT overexpression is observed in PE cases with a poor prognosis. DNA methylation 
has been found to be intact in these cases of PE (Supplemental Material-10) and therefore is not 
responsible for observed TERT overexpression [57]. Decreased expression of SUV4-20H2 has 
been found in these cases. In the presence of intact DNA methylation, SUV4-20H2 would still be 
recruited to that site but to a lesser degree.  Since NT2 was used as a control in the ChIP-qPCR 
experiments, we were able to show that SUV4-20H2 was still recruited to the TERT promoter 
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but we were not able to evaluate the difference in SUV4-20H2 presence from normal brain 
tissue or tissue from the good prognosis subgroup. Our findings are therefore consistent with 
this viable molecular mechanism. Further trials using normal brain tissue controls and some 
samples with a good prognosis classification could provide more robust backing for this 
mechanism, and experiments will be conducted to this end. As they stand, though, these 
findings are consistent with a model wherein decreased expression of SUV4-20H2 leads to loss 
of silencing of TERT and contributes to tumor recurrence (Fig. 11). 
 This is consistent with our findings of down-regulation of this enzyme corresponding to 
up-regulation of several proto-oncogenes, including TERT,  in a subset of pediatric 
ependymoma characterized by a recurrent phenotype. The relevance and strength of this model 
for SUV4-20H2 regulation of TERT justify further investigation of the potential broader role of 
this enzyme in carcinogenesis. Further, the preliminary evidence indicating loss of SUV4-20H2 
gene regions in a subset of PE cases supports investigation of SUV4-20H2 as a potential “driver” 
mutation. Further study of this enzyme holds promise for an increased understanding of the 
mechanisms underlying pediatric ependymoma and potentially of carcinogenesis in general.   
  
Future Directions 
 Further experimentation can go in two different directions. Experiments could focus on 
further clarifying the relationship between SUV4-20H2 and hTERT or could expand out to 
screen for broader/more general functions of SUV4-20H2. Both lines of questioning must be 
addressed if this enzyme and it’s role in carcinogenesis is to be fully understood.  
 Before proceeding to new experiments,  
ChIP-sequencing 
 ChIP-sequencing experiments would help elucidate the broader functioning of 
SUV4-20H2, such as where it exerts effects in this tumor type, in normal brains at different 
developmental time points,  and ultimately in other cancers. As discussed at the end of the 
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results section, this experimentation is already in progress. These experiments will allow for: (1) 
determination of which, if any, other proto-oncogenes SUV4-20H2 binds in proximity to, (2)  
evaluation of the overall binding patterns of SUV4-20H2, (3) determination of which, if any, 
other proto-oncogenes harbor H4K20me2 and/or H4K20me3 modifications, and (4) evaluation 
of the overall patterning of H4K20me2 and H4K20me3 in pediatric ependymomas as compared 
to normal controls.  
 While these experiments primarily seek to further expand this research, they also reach 
back to address some limitations confronted in the ChIP-qPCR experiments. Specifically, they 
should clarify the relationship between SUV4-20H2 and the other three proto-oncogenes 
assayed. It could be the case that SUV4-20H2 simply doesn’t interact with these genes and their 
correlated expression was simply coincidental, or the negative results could have been due to the 
directed nature of ChIP-qPCR experiments. Our primers for these genes may not have been in 
close enough proximity to where SUV4-20H2 binds to regulate them. hTERT was an anomaly in 
it's extent of characterization in PE; it has been studied extensively due to its strong correlation 
with prognosis. This allowed us to predict the most likely region of interaction with SUV4-20H2 
and craft highly specific primers that area. For assessment of interaction with the other three 
proto-oncogenes (ERBB2, ESCO2, IGF-2), we used primers for areas in their promoters that 
fulfilled general criteria for making effective primers but not for specific predicted areas of 
interaction. This could have been addressed in future iterations of ChIP-qPCR by using several 
primers covering disparate regions of each gene. This same effect though is also achieved as a 
component of ChIP-sequencing experimentation. 
Validation of altered protein activity associated with altered gene expression. 
 The ChIP-qPCR experiments discussed in this thesis provide sufficient evidence to claim 
that SUV4-20H2 interacts with the TERT promoter and that H4K20me2 and H4K20me3 
modifications are present at the TERT promoter. However, further experimentation is needed to 
validate the broader claim that decreased SUV4-20H2 expression causes increased hTERT 
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expression.  What we have actually shown so far in regards to that claim is that decreased 
SUV4-20H2 mRNA concentration correlates with increased hTERT mRNA concentration. This 
could be evaluated by performing western blots on the cells for which we have already 
determined the altered expression levels. Relative protein levels could be evaluated for 
correspondence to relative mRNA concentration. 
Confirmation of gene loss corresponding to lower expression of SUV4-20H2. 
 Another similarly basic validation assay that could strengthen the model developed in 
this thesis would be to further investigate the chromosome 19 gene loss observed in a subset of 
PE tumors. This investigation should evaluate the correspondence between gene loss and under 
expression. If corresponding gene loss was found in a significant number of samples in which 
the under expression of SUV4-20H2 was observed, it would validate the findings in this thesis.  
Additionally, it would prompt further investigation into the nature of the gene loss (e.g. 
germline vs. somatic). Germline mutations of SUV4-20H2 would provide strong support for it 
being a "driver" mutation. 
Knockdown and overexpression experiments. 
 Further support could be gained from knockdown and overexpression assays with 
SUV4-20H2 in a model system of nervous system development. This set of experiments could 
provide the most specific and conclusive understanding of the functional interaction between 
SUV4-20H2 and TERT. A time-scale knockdown of SUV4-20H2 (siRNA, lentiviral knockdown; 
halted and fixed at specific time points, e.g. 12h, 24h, 48h) could be performed on cultured 
neurally-restricted cell lines. Time-point isolates could be coincidentally evaluated by western 
blot for SUV4-20H2 protein levels and qPCR for TERT and SUV4-20H2 expression levels. 
Detection of increased TERT transcription associated with progressive SUV4-20H2 decrease 
would be expected given this model.  
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 An overexpression assay in cultured PE cell lines could potentially yield highly 
translatable data. A parallel experiment to the one described above could be conducted and 
TERT expression relative to SUV4-20H2 expression could be assessed. If TERT expression were 
to decrease with increasing SUV4-20H2 presence, that would further substantiate this model 
and provide the impetus for further evaluation of SUV4-20H2 as a potential therapeutic target. 
This construct could be used to also evaluate the broader functioning of SUV4-20H2 if time-
points isolated were screened rather than assayed. 
Summary and Conclusions 
 The overall aims of clinical cancer research are to better define genomic, transcriptomic 
and proteomic differences among malignancies and to relate these determined molecular 
phenotypic patterns to differences in prognosis and treatment response. This thesis provides 
novel insights regarding just one small component of the intricate web of coincident 
mechanisms leading to the development of this and other malignancies.  It is with innumerable 
small insights such as this, though, that those overall aims with be resolved. 
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Epigenetic modifications and chromatin state. 








Differential expression patterns in “good prognosis” and “poor prognosis” 
subgroups of PE. 
Genes used in this permutation analysis of PE microarray data shown in this figure are the top 
1000 highest variance genes. Expression values were calculated relative to mean normal 
(control) expression per gene. (A) Heatmap visualization represents expression levels on a 
spectrum where light green represents the extreme of underexpression, black represents no 
difference, bright red represents the extreme of overexpression. (B) Volcano plot comparing the 
number of significant differentially expressed genes between poor prognosis (PP; Group B) and 





Poor prognosis subgroup is characterized by altered expression of genes related to 
cell cycle regulation, tumor suppression, as well as DNA replication and repair. 
Gene set analysis (GSEA) found groups of biologically related genes that showed altered 
expression in the poor prognosis subgroup. Genes within those groups that showed the most 
significantly altered expression were determined by SAM analysis. Genes are labelled (a-l) in a 
heatmap visualization of most underexpressed genes (B1) and most overexpressed genes (B2) in 
the poor prognosis subgroup, where again light green represents the extreme of 
underexpression, black represents no difference, bright red represents the extreme of 





Proposed model of SUV4-20H2 in cancer. 
Normal function of SUV4-20H2 involves methylation of histone H4 on lysine 20. This 
modification induces compaction of chromatin in that area. Decreased expression of 
SUV4-20H2 is found in a subset of PE. Corresponding increases in expression of numerous 
porto-oncogenes was also found. The proposed model suggests that SUV4-20H2 normally 
regulates the silencing of these genes, and that decreased SUV4-20H2 expression leads to a 
decrease in H4K20 modifications and resulting de-compaction of chromatin surrounding these 






VCU PE samples show differential expression of SUV4-20H2 and proto-oncogenes.   
Raw qPCR results for (A) SUV4-20H2, (B) TERT, (C) ErbB2, (D) Esco2, and (E) IGF-2 were 
analyzed in RStudio. Results were separated into good prognosis (GP) (n=3) and poor prognosis 
(PP) (n=8) subgroups by the same criteria used in microarray analysis. Subgroup mean 
expression was calculated for each proto-oncogene of interest. Bars represent mean log-








Pearson's Product-Moment Correlation: qPCR vs. Microarray
t-value df p-value r
Good Prognosis 8.4822 3 0.003441 0.9797815





qPCR in VCU samples validates microarray differential expression. 
(A) Table of values resulting from Pearson's Product-Moment Correlations for each data set. (B) 
Scatterplot depicting correlation between microarray and qPCR differential expression for poor 
prognosis subgroup. (C) Scatterplot depicting correlation between microarray and qPCR 
differential expression for good prognosis subgroup. 
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Figure 7: 
Antibodies are effective for use in chromatin immunoprecipitation. 
ChIP with antibodies to be used in ChIP-qPCR and ChIP-sequencing experiments was 
performed on NT2 (control) chromatin isolates, followed by PCR with GAPDH primers. 
Subsequent agarose gel electrophoresis shows (A) DNA resulting from SUV4-20H2 antibody 
[rabbit, ActivMotif] on NT2 chromatin isolates, (B) DNA resulting from H4K20me2 antibody 
[rabbit, AbCam] on NT2 chromatin isolates, (C) DNA resulting from H4K20me3 antibody 
[rabbit, AbCam] on NT2 chromatin isolates, and finally (D) DNA resulting from negative control 
non-immune IgG antibody [Epigentek] on NT2 chromatin isolates. Presence of visible DNA 
bands at each antibody validates their ability to bind to chromatin and pull down DNA. 
Comparison to negligible quantities of DNA in the negative control pool validates that this is not 




Schematic showing general binding regions of SUV4-20H2 and other chromatin 
modifiers.  
SUV4-20H2-generated modification boxed in purple. Note location in extreme 5' end of 




SUV4-20H2 binds to chromatin near TERT promoter. 
ChIP-pulldown DNA  from three PE tumor samples (VC-273, VC300, VC-1266) was quantified 
using qPCR for TERT -807 primers. Mean triplicate raw Ct values for SUV4-20H2 and mock IP 
were normalized to input control. Bars represent input-normalized fold-enrichment over 
background signal. Error bars represent standard deviation between replicates (negligible). P-





ChIP-qPCR Results with anti-SUV4-20H2. 
Values for fold-enrichment, error, and significance for each sample-gene pair. Fold-enrichment 
values depicted in Figure 8 are boxed to highlight the distinction between TERT enrichment and 
enrichment of the other three proto-oncogenes. TERT was the only gene found in significant 








H4K20me2 and H4K20m3 modifications are present in chromatin near TERT 
promoter. 
ChIP-pulldown DNA  from three PE tumor samples (VC-273, VC300, VC-1266) was quantified 
using qPCR for TERT -807 primers. Mean triplicate raw Ct values for (A) H4K20me2 and (B) 
H4K20me3 and mock IP were normalized to input control. Bars represent input-normalized 
fold-enrichment over background signal. Error bars represent standard deviation between 
replicates (negligible). For both test antibody pulldowns, P-values were calculated between the 




ChIP-qPCR Results with anti-H4K20me2. 
Values for fold-enrichment, error, and significance for each sample-gene pair. Fold-enrichment 
values depicted in Figure 9A are boxed to highlight the distinction between TERT enrichment 
and enrichment of the other three proto-oncogenes. TERT was the only gene found in significant 




ChIP-qPCR Results with anti-H4K20me3. 
Values for fold-enrichment, error, and significance for each sample-gene pair. Fold-enrichment 
values depicted in Figure 9B are boxed to highlight the distinction between TERT enrichment 
and enrichment of the other three proto-oncogenes. TERT was the only gene found in significant 
concentrations following H4K20me3 IP. 
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Figure 11:  
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Model for dysregulation of TERT by SUV4-20H2 leading to PE. 
SUV4-20H2 normally binds the TERT promoter and methylates histone H4 lysine 20, which 
causes compaction of chromatin in that area. SUV4-20H2 expression is decreased in a subset of 
PE. This leads to a decrease in these modifications and resulting de-compaction of chromatin at 
the TERT gene. This allows for increased TERT expression and corresponding effects that cause 
increased tumorigenicity [44]. 
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SUPPLEMENTARY MATERIALS 
1.   PLIER Method 
"  
2. Permutation testing parameters and calculations: formulas and calculations for 
rejection criteria, test statistics, and p-values. 
Wilcoxon Signed Ranks Test: 
m = # observations in Group A 
n = # observations in Group B 
Possible permutations for m and n observations = ((m+n)!)/(m!n!) 
Rejection Region = (((m+n)!)/(m!n!)) 
z = [T-((N(N+1))/4)]/[SQRT((N(N+1)(2N+1))/24)] 
di = signed difference between two scores 
N = (# matched pairs) - (# matched pairs where di=0) 
T = smaller of two sums of like signed ranks 
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3. GSEA method overview. (A) An expression data set sorted by correlation with 
phenotype, the corresponding heat map, and the “gene tags,” i.e., location of genes from a 
set S within the sorted list. (B) Plot of the running sum for S in the data set, including the 
location of the maximum enrichment score (ES) and the leading-edge subset. [25] 
"  
4. SAM methodology: principal calculations [26]. 
"  
!66
5. Agilent 2100 Bioanalyzer: RNA 6000 Pico Kit protocol 
Essential Measurement Practices 
• Handle and store all reagents according to the instructions on the label of the individual box. 
• Avoid sources of dust or other contaminants. Foreign matter in reagents and samples or in the 
wells of the chip will interfere with assay results. 
• Allow all reagents to equilibrate to room temperature for 30 minutes before use. 
• Protect dye and dye mixtures from light. Remove light covers only when pipetting. The dye 
decomposes when exposed to light and this reduces the signal intensity. 
• Always insert the pipette tip to the bottom of the well when dispensing the 
liquid. Placing the pipette at the edge of the well may lead to poor results. 
• Always wear gloves when handling RNA and use RNase-free tips, microfuge 
tubes and water. 
• It is recommended to heat denature all RNA samples and RNA ladder 
before use for 2 minutes and 70 °C (once) and keep them on ice (Special attention is needed for 
Ladder preparation. Please read “Preparing the RNA ladder after arrival” on page 14 of the Kit 
guide). 
• Do not touch the Agilent 2100 bioanalyzer during analysis and never place it on vibrating 
surface. 
• Always vortex the dye concentrate for 10 seconds before preparing the gel-dye mix. 
• Use a new syringe and electrode cleaners with each new kit. 
• Use loaded chips within 5 minutes after preparation. Reagents might evaporate, leading to 
poor results. 
• To prevent contamination (e.g. RNase) problems, it is strongly recommended to use a 
dedicated electrode cartridge for RNA assays. 
Preparing the RNA Ladder after Arrival: 
1. After reagent kit arrival, spin ladder down. 
2. Heat denature it for 2 min at 70 °C. 
3. Immediately cool down the vial on ice. 
4. Add 90 µl of RNase-free water and mix thoroughly. 
5. Prepare aliquots in 0,5 ml RNase-free vials (Eppendorf Safe-lock PCR clean or 
Eppendorf DNA LoBind microcentrifuge tubes) with the required amount for a typical 
daily use. 
6. Store aliquots at -70 °C. After initial heat denaturing, the frozen aliquots should not be 
heat denatured again. 
7. Before use thaw ladder aliquots and keep them on ice (avoid extensive warming). 
Setting up the Chip Priming Station:  
1. Replace the syringe 
a. Unscrew the old syringe from the lid of the chip priming station. 
b. Release the old syringe from the clip. Discard the old syringe. 
c. Remove the plastic cap of the new syringe and insert it into the clip. 
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d. Slide it into the hole of the luer lock adapter and screw it tightly to the priming 
station. 
2. Adjust the base plate: 
a. Open the chip priming station by pulling the latch. 
b. Using a screwdriver, open the screw at the underside of the base plate. 
c. Lift the base plate and insert it again in position C. Retighten the screw. 
3. Adjust the syringe clip: 
a. Release the lever of the clip and slide it up to the top position. 
Preparing the Gel: 
1. Pipette 550 µl of RNA 6000 Pico gel matrix (red ) into a spin filter. 
2. Centrifuge at 1500 g ± 20 % for 10 minutes at room temperature. 
3. Aliquot 65 µl filtered gel into 0.5 ml RNase-free microfuge tubes. Use filtered gel within 
4 weeks. 
Preparing the Gel-Dye Mix: 
1. Allow the RNA 6000 Pico dye concentrate (blue ) to equilibrate to room temperature for 
30 min. 
2. Vortex RNA 6000 Pico dye concentrate (blue ) for 10 seconds, spin down and add 1 µl of 
dye into a 65 µl aliquot of filtered gel. 
3. Vortex solution well. Spin tube at 13000 g for 10 min at room temperature. Use prepared 
Gel-Dye mix within one day. 
Loading the Gel-Dye Mix: 
1. Put a new RNA 6000 Pico chip on the chip priming station. 
2. Pipette 9.0 µl of gel-dye mix in the well marked "G". 
3. Make sure that the plunger is positioned at 1 ml and then close the chip priming station. 
4. Press plunger until it is held by the clip. 
5. Wait for exactly 30 seconds then release clip. 
6. Wait for 5 s. Slowly pull back plunger to 1ml position. 
7. Open the chip priming station and pipette 9.0 µl of gel-dye mix in the wells marked "G". 
8. Discard the remaining gel-dye mix. 
Loading the RNA 6000 Pico Conditioning Solution and Marker: 
1. Pipette 9.0 µl of the RNA 6000 Pico Conditioning Solution (white ) in the well marked 
CS. 
2. Pipette 5 µl of RNA 6000 Pico marker (green ) in all 11 sample wells and in the well 
marked {ladder}. 
Loading the Diluted Ladder and Samples: 
1. Pipette 1 µl of the heat denatured and aliquoted ladder in the well marked {ladder}. 
2. Pipette 1 µl of sample in each of the 11 sample wells. Pipette 1 µl of RNA 6000 Pico 
Marker (green) in each unused sample well. 
3. Put the chip in the adapter of the IKA vortexer and vortex for 1 min at the indicated 
setting (2400 rpm). 
4. Run the chip in the Agilent 2100 bioanalyzer within 5 min. 
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6. Nanodrop protocol 
For best results, ensure measurement pedestal surfaces are clean. 
1. With the sampling arm open, load 1-2 mL of de-ionized water onto the lower measurement pedestal. 
2. With the sampling arm in the down position, start the NanoDrop software by selecting the following 
path: Start à Programs à NanoDrop à ND-1000 V3.1.0 
3. When the software starts, you should see this message: 
a. “Ensure pedestals are clean…Click OK to initialize instrument.” 
b. Click OK. 
c. The messages “Initializing Spectrometer- please wait” will appear. 
When these messages disappear, the instrument will be ready for use. 
All data taken will automatically be logged in the appropriate archive file. 
4. With the sampling arm open, wipe both pedestals with a laboratory wipe. 
5. Load a reference blank (the buffer, solvent, or carrier liquid used with your samples) onto the lower 
measurement pedestal. 
a. Lower the sampling arm into the down position. 
b. The sample column is automatically drawn between the upper and lower measurement 
pedestals and the spectral measurement made. 
Confirm that reference (blank) solution and solvent are the same material! 
. 
6. Click on the Blank (F3) button to store the blank reference. 
a. Wipe off both pedestals. 
7. Analyze a fresh replicate of the blanking solution as though it were a sample by selecting Measure 
(F1). 
(The result should be a spectrum that varies no more than 0.050 A (10mm absorbance equivalent).) 
a. Wipe the blank from both measurement pedestal surfaces with a laboratory wipe. 
b. Repeat the blanking process until the spectrum is within 0.005 A (1mm path). 
8. Analyze your sample. 
a. Mix the sample well prior to measurement. 
After measuring a large number of samples, clean the areas around the upper and lower pedestals 
thoroughly. This will prevent cross-contamination from previous samples and distortion of low-level 
measurements. 
Clean all surfaces with de-ionized water after the final sample measurement. 
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7. Chromatin Immunoprecipitation: specific volumes (chromatin and chip buffer) 
8. Primers Designed for qPCR experiments. Microarray-qPCR: exon primers, to 
measure transcript levels. ChIP-qPCR: promoter primers, to measure DNA fragments 
associated with SUV4-20H2 or H4K20me2/H4K20me3-modified histones. All primers were 
designed to avoid hairpin formation and hetero-/homo-dimerization (DNA Mfold). Primers 
were designed to avoid variant bias (Blast). 
"  






9. MeDIP & 450k methylation array. Group A is associated with poorer prognosis in this 
study. DNA methylation is found to be intact in regions surrounding -807 and -575 positions 
in TERT promoter [35] Primers for CpG islands surrounding both of these sequences were 
developed, those for the TSS -575 position (5p-1,295,759) were most efficient and were used 
for this assay. -575 region methylation data in poor prognosis group is boxed in red. 
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